Stocklytics Platform
Asset logo for symbol PYXS
Pyxis Oncology
PYXS52
$3.55arrow_drop_up1.13%$0.04
Penny Stock
Asset logo for symbol PYXS
PYXS52

$3.55

arrow_drop_up1.13%
Key Stats
Open$3.50
Prev. Close$3.51
EPS-1.27
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$208.57M
PE Ratio-
LOWHIGH
Day Range3.46
3.65
52 Week Range1.35
6.85
Ratios
Revenue-
EBITDA Margin %-
EPS-1.27
Fundamentals
Gross Profit-
Payout Ratio-
Industry average yield2.89%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

PYXS-
US Healthcare Sector-
US Market-
warning

PYXS / Market

PYXS lose to the US Market which returned 1.73% over the last twenty four hours.
warning

PYXS / Healthcare Sector

PYXS lose to the US Healthcare sector which returned 1.88% over the last twenty four hours.

Pyxis Oncology (PYXS) Statistics

Pyxis Oncology, Inc. (PYXS) is a leading biotechnology company specializing in oncology research and development. As a pioneer in the field of cancer therapeutics, Pyxis is dedicated to advancing the understanding and treatment of cancer through innovative science and cutting-edge technology. With a team of world-class scientists and industry experts, Pyxis is at the forefront of the fight against cancer, working tirelessly to develop breakthrough therapies that have the potential to transform patients' lives.
When it comes to valuation metrics, Pyxis Oncology, Inc. (PYXS) is in a strong position. The company's stock has performed exceedingly well compared to its sector, demonstrating its ability to generate impressive returns for investors. In addition, Pyxis has a solid financial foundation, with robust fundamentals and a healthy profit margin. This is reflected in its stock price, which has seen consistent growth over the years. Furthermore, Pyxis has managed its debt effectively, resulting in a favorable enterprise to EBITDA ratio. This indicates that the company is well-positioned to handle its financial obligations and generate substantial profits.
add Pyxis Oncology to watchlist

Keep an eye on Pyxis Oncology

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Pyxis Oncology (PYXS) stock's performance compared to its sector and the market over the past year?

Over the past year, Pyxis Oncology (PYXS) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 35.30%, Pyxis Oncology has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 71.47%, it has fallen short of the market average. This comparison highlights Pyxis Oncology's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Pyxis Oncology (PYXS) stock?

The PE ratio for Pyxis Oncology (PYXS) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Pyxis Oncology (PYXS) stock?

The Earnings Per Share (EPS) for Pyxis Oncology (PYXS), calculated on a diluted basis, is -$1.27. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Pyxis Oncology (PYXS) stock?

The operating margin for Pyxis Oncology (PYXS) is -409.25%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Pyxis Oncology (PYXS) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Pyxis Oncology (PYXS) is -$63.16M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Pyxis Oncology (PYXS) have?

Pyxis Oncology (PYXS) has a total debt of $20.87M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$5.67M.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media